These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 30197259)

  • 1. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.
    Owen DH; Wei L; Bertino EM; Edd T; Villalona-Calero MA; He K; Shields PG; Carbone DP; Otterson GA
    Clin Lung Cancer; 2018 Nov; 19(6):e893-e900. PubMed ID: 30197259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
    Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S
    Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
    Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
    Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.
    Haratani K; Hayashi H; Chiba Y; Kudo K; Yonesaka K; Kato R; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Nakagawa K
    JAMA Oncol; 2018 Mar; 4(3):374-378. PubMed ID: 28975219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
    Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
    Lung Cancer; 2019 Apr; 130():159-161. PubMed ID: 30885338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis.
    Sonehara K; Tateishi K; Araki T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
    Oncology; 2021; 99(5):271-279. PubMed ID: 33631764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.
    Inoue T; Tamiya M; Tamiya A; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Kunimasa K; Kimura M; Suzuki H; Hirashima T; Atagi S; Imamura F
    Clin Lung Cancer; 2018 Mar; 19(2):e171-e176. PubMed ID: 29133121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
    Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
    Lee JS; Lee KH; Cho EK; Kim DW; Kim SW; Kim JH; Cho BC; Kang JH; Han JY; Min YJ; Park K
    Lung Cancer; 2018 Aug; 122():234-242. PubMed ID: 30032838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
    Duma N; Abdel-Ghani A; Yadav S; Hoversten KP; Reed CT; Sitek AN; Enninga EAL; Paludo J; Aguilera JV; Leventakos K; Lou Y; Kottschade LA; Dong H; Mansfield AS; Manochakian R; Adjei AA; Dronca RS
    Oncologist; 2019 Nov; 24(11):e1148-e1155. PubMed ID: 31036771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
    Tournoy KG; Thomeer M; Germonpré P; Derijcke S; De Pauw R; Galdermans D; Govaert K; Govaerts E; Schildermans R; Declercq I; De Brucker N; Pat K; Van Herreweghe R; Van Zandweghe L; Vanmaele L; Van Damme V; Marien H; De Craene S; Fabry I; Alexander P; Vercauter P; Demedts I
    Lung Cancer; 2018 Jan; 115():49-55. PubMed ID: 29290261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
    Voong KR; Hazell SZ; Fu W; Hu C; Lin CT; Ding K; Suresh K; Hayman J; Hales RK; Alfaifi S; Marrone KA; Levy B; Hann CL; Ettinger DS; Feliciano JL; Peterson V; Kelly RJ; Brahmer JR; Forde PM; Naidoo J
    Clin Lung Cancer; 2019 Jul; 20(4):e470-e479. PubMed ID: 31031204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
    Fukihara J; Sakamoto K; Koyama J; Ito T; Iwano S; Morise M; Ogawa M; Kondoh Y; Kimura T; Hashimoto N; Hasegawa Y
    Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
    Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
    Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy.
    Hu WT; Zhang Q; Zhang Z; He X; Zhou M; Guo Y; Wang X
    Front Immunol; 2023; 14():1112409. PubMed ID: 36949952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.